Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG10 in Symptomatic Transthyretin Amyloid Polyneuropathy
NCT04418024Phase 3Withdrawn
- Sponsor
- BridgeBio Pharma
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acoramidis in transthyretin amyloid polyneuropathy (ATTR-PN), sponsored by BridgeBio Pharma. Planned start Oct 2020; status: withdrawn.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid polyneuropathy (ATTR-PN)
Beyond the preview
Go deeper on NCT04418024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418024.